Gender disparities in evidence-based statin therapy in patients with cardiovascular disease

American Journal of Cardiology

Volumn 115, Issue 1, 2015, Pages 21-26

  Virani, Salim S ^a,b,c   Woodard, Lechauncy D ^a   Ramsey, David J ^a   Urech, Tracy H ^a   Akeroyd, Julia M ^a   Shah, Tina ^a,b   Deswal, Anita ^a,b   Bozkurt, Biykem ^a,b   Ballantyne, Christie M ^b,c   Petersen, Laura A ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; RESIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE DISPARITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; VETERANS HEALTH; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; FOLLOW UP; MULTICENTER STUDY; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; SEX RATIO; TIME; UNITED STATES;

AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SEX FACTORS; TEXAS; TIME FACTORS;

EID: 84915775321     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.09.041     Document Type: Article

References (20)

1. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, and A.M. Gotto Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
3. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
4. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
5. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
6. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek, J. Tsai Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
7. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, N.K. Wenger Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
8. S.V. Arnold, J.A. Spertus, F. Tang, H.M. Krumholz, W.B. Borden, S.A. Farmer, H.H. Ting, and P.S. Chan Statin use in outpatients with obstructive coronary artery disease Circulation 124 2011 2405 2410
9. S.S. Virani, L.D. Woodard, S.S. Chitwood, C.R. Landrum, T.H. Urech, D. Wang, J. Murawsky, C.M. Ballantyne, and L.A. Petersen Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease Am Heart J 162 2011 725 732
10. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, P.W. Wilson American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
11. L.D. Woodard, C.R. Landrum, T.H. Urech, J. Profit, S.S. Virani, and L.A. Petersen Treating chronically ill people with diabetes mellitus with limited life expectancy: implications for performance measurement J Am Geriatr Soc 60 2012 193 201
12. S.S. Virani, L.D. Woodard, C.R. Landrum, K. Pietz, D. Wang, C.M. Ballantyne, and L.A. Petersen Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines Am Heart J 161 2011 1140 1146
13. L.D. Woodard, C.R. Landrum, T.H. Urech, D. Wang, S.S. Virani, and L.A. Petersen Impact of clinical complexity on the quality of diabetes care Am J Manag Care 18 2012 508 514
14. S.S. Virani, D. Wang, L.D. Woodard, S.S. Chitwood, C.R. Landrum, F.J. Zieve, C.M. Ballantyne, and L.A. Petersen Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care J Clin Lipidol 6 2012 545 552
15. L.D. Woodard, T. Urech, C.R. Landrum, D. Wang, and L.A. Petersen Impact of comorbidity type on measures of quality for diabetes care Med Care 49 2011 605 610
16. L.A. Petersen, K. Pietz, L.D. Woodard, L.D. Woodard, and M. Byrne Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes Med Care 43 2005 61 67
17. L.A. Petersen, L.D. Woodard, L.M. Henderson, T.H. Urech, and K. Pietz Will hypertension performance measures used for pay-for-performance programs penalize those who care for medically complex patients? Circulation 119 2009 2978 2985
18. S. Mora, R.J. Glynn, J. Hsia, J.G. MacFadyen, J. Genest, and P.M. Ridker Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials Circulation 121 2010 1069 1077
19. Q.A. Truong, S.A. Murphy, C.H. McCabe, A. Armani, and C.P. Cannon Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22 Circ Cardiovasc Qual Outcomes 4 2011 328 336
20. Available at: http://vaww.car.rtp.med.va.gov/programs/pm/performance.aspx. Accessed on January 2, 2014.